Peptide Regulation: A Living Tracker

Peptide regulation is not a single framework – it is a patchwork of overlapping systems that treat the same molecule differently depending on the country, the intended use, and whether it is marketed for human consumption. A compound that is a lawfully compounded prescription medication at a US 503A pharmacy may simultaneously be an unauthorised medicine under UK law, a Schedule 4 prescription-only substance in Australia, and an unregulated research chemical in much of the EU.

The confusion is compounded by the fact that “research use only” labelling does not confer any blanket legal protection. Regulators in the US, UK, and Australia have all taken enforcement action against companies selling peptides labelled for research purposes when the evidence suggests they are marketed or intended for human use.

This page serves as a master index linking to every PeptideGuider article covering regulation, legality, and enforcement. Each linked page is maintained independently and contains the full detail for its jurisdiction or topic. Use this page to find the right starting point, then follow the link for depth.

The table below summarises the regulatory approach in each country or region covered by PeptideGuider, with a link to the full analysis. Enforcement intensity, legal frameworks, and the distinction between approved drugs, compounded medications, and grey-market products vary in every jurisdiction.

Jurisdiction	Regulatory Body	Approach	Enforcement Level	Full Article
United States	FDA	Category-based compounding framework; “research use” tolerated but actively targeted when marketed for human use	High (escalating)	US Legality
United Kingdom	MHRA	Three-law framework (MDA 1971, HMR 2012, PSA 2016); personal importation tolerated in small quantities	Moderate (supply-focused)	UK Legality
Australia	TGA	SUSMP scheduling system; most peptides Schedule 4 (Rx) or Schedule 9 (prohibited); SAS/Authorised Prescriber pathways	Very high	AU Legality
Canada	Health Canada	Federal drug scheduling; compounding governed by provincial pharmacy colleges	Moderate	CA Legality
European Union	EMA + national agencies	EMA sets centralised framework; enforcement varies dramatically by member state	Variable (country-dependent)	EU Legality
Germany	BfArM / AMG	Arzneimittelgesetz (AMG) treats peptides as medicinal products; Anti-Doping-Gesetz adds criminal layer for performance compounds	High (strictest in EU)	Germany Legality
New Zealand	Medsafe / MCC	Medicines Classification Committee scheduling; aligns with but is distinct from TGA	Moderate (rising)	NZ Legality

The bottom line: Australia has the most restrictive peptide regulation among English-speaking countries, with active enforcement including border seizures and prosecutions, while the US is in the most dynamic period of regulatory change with the PCAC reclassification process underway and GLP-1 compounding rules shifting.

The US regulatory environment for peptides is structured around the FDA’s three-category system for bulk drug substances eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. This framework determines which peptides licensed compounding pharmacies can legally prepare for patients with valid prescriptions. It is entirely separate from the “research use only” market, which operates in a legal grey zone.

Three articles cover the US framework in depth:

• FDA Category 1 vs Category 2 – explains the three-category system in full, including the 503A versus 503B compounding distinction and the history of the NECC compounding crisis that shaped the current framework.
• RFK Peptide Reclassification Tracker – tracks the full reclassification timeline from the September 2023 Category 2 placement through the February 2026 HHS announcement, the April 2026 formal Category 2 removals, and the path to PCAC review. This is the single most dynamic regulatory story in the peptide space.
• PCAC July 2026 Meeting Tracker – covers the specific agenda, logistics, and expected outcomes of the July 23-24, 2026 PCAC meeting at FDA White Oak Campus, where the first group of peptides will be evaluated for potential Category 1 reclassification.

The UK regulates peptides through the Medicines and Healthcare products Regulatory Agency (MHRA) under a three-law framework: the Misuse of Drugs Act 1971, the Human Medicines Regulations 2012, and the Psychoactive Substances Act 2016. Peptides intended for human therapeutic use are classified as medicines requiring marketing authorisation, but personal importation in small quantities has historically been tolerated rather than actively prosecuted. Two articles cover the UK framework:

• Are Peptides Legal in the UK? – covers the legal framework, the personal importation question, and where UK regulation sits relative to other jurisdictions.
• MHRA Peptide Enforcement History – documents the full MHRA enforcement timeline from 2006 to 2026, including seizure operations, prosecution cases, and participation in INTERPOL Pangea operations.

Australia’s Therapeutic Goods Administration operates the most restrictive peptide regulatory environment among English-speaking countries, using the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) to classify individual compounds. Most research peptides fall under Schedule 4 (prescription-only), while some – most notably Melanotan II – are classified as Schedule 9 (prohibited). The TGA has actively prosecuted importers and suppliers, with penalties for individuals exceeding AUD $200,000 and corporate penalties reaching AUD $1 million or more. Two articles cover the Australian framework:

• Are Peptides Legal in Australia? – covers the SUSMP scheduling system, SAS and Authorised Prescriber access pathways, and the practical reality of Australian enforcement.
• TGA Enforcement Timeline – documents the complete enforcement history, including the Peptide Clinics prosecution, Melbourne seizure operations, and scheduling decision evidence bases.

Four additional jurisdiction pages cover regulatory frameworks beyond the US, UK, and Australia:

• Are Peptides Legal in Canada? – federal scheduling, provincial compounding pharmacy governance, and the Health Canada enforcement posture.
• Are Peptides Legal in the EU? – EMA centralised authorisation framework and the significant variation in enforcement across member states.
• Are Peptides Legal in Germany? – the Arzneimittelgesetz (AMG) medicinal products framework and the Anti-Doping-Gesetz, which criminalises possession of performance-enhancing substances including many peptides.
• Are Peptides Legal in New Zealand? – Medsafe and the Medicines Classification Committee scheduling system, which aligns with but operates independently from the Australian TGA.

The regulation of compounded GLP-1 medications – particularly semaglutide and tirzepatide – has become a distinct and fast-moving regulatory sub-topic. The intersection of drug shortage declarations, 503A/503B compounding access, FDA enforcement against telehealth companies, and the OFA v FDA litigation created a unique regulatory environment unlike anything else in the peptide space. The Compounded vs Branded GLP-1s article covers this landscape in full, including the 503B bulks proposal published April 30, 2026, and the comment deadline of June 30, 2026.

The following timeline summarises the major regulatory inflection points covered across PeptideGuider’s regulatory articles. Each event is covered in depth by the linked article.

Date	Event	Covered In
Sep 2023	FDA places 19 peptides on Category 2 restricted list	RFK Tracker
Sep 2024	5 peptides (CJC-1295, ipamorelin, TA-1, AOD-9604, selank) referred to PCAC	RFK Tracker
Oct 2024	Tirzepatide drug shortage resolved	Compounded vs Branded
Dec 2024	PCAC votes against AOD-9604 for 503A list	AOD-9604 Guide
Feb 2025	Semaglutide drug shortage resolved	Compounded vs Branded
Feb 27, 2026	HHS Secretary Kennedy announces intent to reclassify ~14 of 19 Category 2 peptides (JRE #2461)	RFK Tracker
Mar 6, 2026	Peptide Sciences voluntarily shuts down under FDA/FTC pressure	US Legality
Apr 1, 2026	Foundayo (orforglipron) FDA approval – first oral non-peptide GLP-1	Orforglipron Guide
Apr 15, 2026	FDA formally removes 12 peptides from Category 2; confirms PCAC dates	RFK Tracker
Apr 30, 2026	503B bulks proposal published (FR docket 2026-08552); comment deadline Jun 30	Compounded vs Branded
Jul 23-24, 2026	PCAC meeting at FDA White Oak Campus (BPC-157, epitalon, semax, emideltide on agenda)	PCAC Tracker

The bottom line: The July 2026 PCAC meeting is the single most consequential near-term regulatory event for the peptide space, while the GLP-1 compounding landscape faces its own distinct set of regulatory pressures with the 503B bulks proposal and the pending OFA v FDA appellate decision.

Regulation does not exist in a vacuum – it responds to market forces, enforcement priorities, and public attention. Three PeptideGuider articles provide the demand-side and market context that shapes regulatory action:

• State of the Peptide Market 2026 – covers the “three markets” framework (branded therapeutics, lawful compounding, grey market), the $50B+ global peptide therapeutics market, and the tension between enforcement and reclassification.
• Chinese Peptides Trend Explainer – covers the import pipeline, Chinese peptide API production, CBP seizure data, and the five converging forces driving grey-market growth.
• Peptides Rogan Has Discussed and Peptides Huberman Has Discussed – document how podcast coverage has driven consumer awareness and regulatory attention, including the RFK announcement on JRE #2461 that triggered the formal reclassification process.

Regardless of a compound’s legal status, the quality of what is actually in the vial is a separate and equally important question. Two foundation articles cover the practical tools for assessing product quality:

• How to Evaluate Peptide Vendors – third-party testing as the decisive quality signal, vendor red flags, and the market consolidation narrative following vendor shutdowns and prosecutions.
• How to Read a Certificate of Analysis – what HPLC purity, MS identity, endotoxin, and heavy metals fields actually tell you, the distinction between purity and net peptide content, and how to spot fraudulent COAs.